The DOI matches its Crossref record; 152 of the 152 references it cites were found in a registry or an index.
In vivo delivery of miRNAs for cancer therapy: Challenges and strategies
Open accessAbstract
MicroRNAs (miRNAs), small non-coding RNAs, can regulate post-transcriptional gene expressions and silence a broad set of target genes. miRNAs, aberrantly expressed in cancer cells, play an important role in modulating gene expressions, thereby regulating downstream signaling pathways and affecting cancer formation and progression. Oncogenes or tumor suppressor genes regulated by miRNAs mediate cell cycle progression, metabolism, cell death, angiogenesis, metastasis and immunosuppression in cancer. Recently, miRNAs have emerged as therapeutic targets or tools and biomarkers for diagnosis and therapy monitoring in cancer. Since miRNAs can regulate multiple cancer-related genes simultaneously, using miRNAs as a therapeutic approach plays an important role in cancer therapy. However, one of the major challenges of miRNA-based cancer therapy is to achieve specific, efficient and safe systemic delivery of therapeutic miRNAs In vivo. This review discusses the key challenges to the development of the carriers for miRNA-based therapy and explores current strategies to systemically deliver miRNAs to cancer without induction of toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: The Role of microRNAs in the Tumorigenesis of Ovarian Cancer
Leva, G. D., & Croce, C. M. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00153 · Cited by 98
RetractedBartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14
Lee, R. C., Feinbaum, R. L., & Ambros, V. (1993) · Cell · doi:10.1016/0092-8674(93)90529-y · Cited by 12,948
Valadi, H., Ekström, K., Bossios, A., Sjöstrand, M., Lee, J. J., & Lötvall, J. O. (2007) · Nature Cell Biology · doi:10.1038/ncb1596 · Cited by 12,834
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Boussif, O., Lezoualc'h, F., Zanta, M. A., Mergny, M. D., Scherman, D., Demeneix, B., & Behr, J. P. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.16.7297 · Cited by 6,247
Chen, X., Ba, Y., Ma, L., Cai, X., Yin, Y., Wang, K., Guo, J., Zhang, Y., Chen, J., Guo, X., et al. (2008) · Cell Research · doi:10.1038/cr.2008.282 · Cited by 4,560
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8
Heil, F., Hemmi, H., Hochrein, H., Ampenberger, F., Kirschning, C., Akira, S., Lipford, G., Wagner, H., & Bauer, S. (2004) · Science · doi:10.1126/science.1093620 · Cited by 3,947
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
miR-15 and miR-16 induce apoptosis by targeting BCL2
Cimmino, A., Calin, G. A., Fabbri, M., Iorio, M. V., Ferracin, M., Shimizu, M., Wojcik, S. E., Aqeilan, R. I., Zupo, S., Dono, M., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506654102 · Cited by 3,517
Biodegradable nanoparticles for drug and gene delivery to cells and tissue
Panyam, J., & Labhasetwar, V. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00228-4 · Cited by 3,361
Arroyo, J. D., Chevillet, J. R., Kroh, E. M., Ruf, I. K., Pritchard, C. C., Gibson, D. F., Mitchell, P. S., Bennett, C. F., Pogosova-Agadjanyan, E. L., Stirewalt, D. L., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019055108 · Cited by 3,294
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 1×
“For example, therapeutic mAbs targeting the ERBB family including epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) showed significant therapeutic effect when treating patients with solid tumors [6,7].”
BackgroundUnique microRNA molecular profiles in lung cancer diagnosis and prognosis
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.025 · Cited by 3,023
MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins
Vickers, K. C., Palmisano, B. T., Shoucri, B. M., Shamburek, R. D., & Remaley, A. T. (2011) · Nature Cell Biology · doi:10.1038/ncb2210 · Cited by 2,741
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Control of translation and mRNA degradation by miRNAs and siRNAs: Table 1.
Valencia-Sanchez, M. A., Liu, J., Hannon, G. J., & Parker, R. (2006) · Genes & Development · doi:10.1101/gad.1399806 · Cited by 2,060
Chargaff, E., & Davidson, J. N. (1955) · Cited by 2,043
MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review
Iorio, M. V., & Croce, C. M. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201100209 · Cited by 1,739
Lawrie, C. H., Gal, S., Dunlop, H. M., Pushkaran, B., Liggins, A. P., Pulford, K., Banham, A. H., Pezzella, F., Boultwood, J., Wainscoat, J. S., et al. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2008.07077.x · Cited by 1,735
MicroRNA-Directed Cleavage of HOXB8 mRNA
Yekta, S., Shih, I.-H., & Bartel, D. P. (2004) · Science · doi:10.1126/science.1097434 · Cited by 1,702
Functional delivery of viral miRNAs via exosomes
Pegtel, D. M., Cosmopoulos, K., Thorley-Lawson, D. A., van Eijndhoven, M. A. J., Hopmans, E. S., Lindenberg, J. L., de Gruijl, T. D., Würdinger, T., & Middeldorp, J. M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914843107 · Cited by 1,641
MicroRNA: Biogenesis, Function and Role in Cancer
MacFarlane, L.-A., & R. Murphy, P. (2010) · Current Genomics · doi:10.2174/138920210793175895 · Cited by 1,584
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
Prabhakar, U., Maeda, H., Jain, R. K., Sevick-Muraca, E. M., Zamboni, W., Farokhzad, O. C., Barry, S. T., Gabizon, A., Grodzinski, P., & Blakey, D. C. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4561 · Cited by 1,485
Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H.-W., Chang, T.-C., Vivekanandan, P., Torbenson, M., Clark, K. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.021 · Cited by 1,452
Lièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
MicroRNAs bind to Toll-like receptors to induce prometastatic inflammatory response
Fabbri, M., Paone, A., Calore, F., Galli, R., Gaudio, E., Santhanam, R., Lovat, F., Fadda, P., Mao, C., Nuovo, G. J., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209414109 · Cited by 1,434
Exploring polyethylenimine‐mediated DNA transfection and the proton sponge hypothesis
Akinc, A., Thomas, M., Klibanov, A. M., & Langer, R. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.696 · Cited by 1,337
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA
Judge, A. D., Sood, V., Shaw, J. R., Fang, D., McClintock, K., & MacLachlan, I. (2005) · Nature Biotechnology · doi:10.1038/nbt1081 · Cited by 1,250
Xiao, C., Srinivasan, L., Calado, D. P., Patterson, H. C., Zhang, B., Wang, J., Henderson, J. M., Kutok, J. L., & Rajewsky, K. (2008) · Nature Immunology · doi:10.1038/ni1575 · Cited by 1,228
Jansson, M. D., & Lund, A. H. (2012) · Molecular Oncology · doi:10.1016/j.molonc.2012.09.006 · Cited by 1,099
Multistage nanoparticle delivery system for deep penetration into tumor tissue
Wong, C., Stylianopoulos, T., Cui, J., Martin, J., Chauhan, V. P., Jiang, W., Popović, Z., Jain, R. K., Bawendi, M. G., & Fukumura, D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018382108 · Cited by 1,062
Panyam, J., Zhou, W., Prabha, S., Sahoo, S. K., & Labhasetwar, V. (2002) · The FASEB Journal · doi:10.1096/fj.02-0088com · Cited by 1,044
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
Arora, A., & Scholar, E. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084145 · Cited by 1,014
Current status of polymeric gene delivery systems☆
PARK, T., JEONG, J., & KIM, S. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.03.007 · Cited by 944
Blood Cell Origin of Circulating MicroRNAs: A Cautionary Note for Cancer Biomarker Studies
Pritchard, C. C., Kroh, E., Wood, B., Arroyo, J. D., Dougherty, K. J., Miyaji, M. M., Tait, J. F., & Tewari, M. (2012) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-11-0370 · Cited by 879
RNA interference in the clinic: challenges and future directions
Pecot, C. V., Calin, G. A., Coleman, R. L., Lopez-Berestein, G., & Sood, A. K. (2011) · Nature Reviews Cancer · doi:10.1038/nrc2966 · Cited by 820
Biodegradable poly(lactic acid) polymers
Kulkarni, R. K., Moore, E. G., Hegyeli, A. F., & Leonard, F. (1971) · Journal of Biomedical Materials Research · doi:10.1002/jbm.820050305 · Cited by 799
An unconventional role for miRNA: let-7 activates toll-like receptor 7 and causes neurodegeneration
Lehmann, S. M., Krüger, C., Park, B., Derkow, K., Rosenberger, K., Baumgart, J., Trimbuch, T., Eom, G., Hinz, M., Kaul, D., et al. (2012) · Nature Neuroscience · doi:10.1038/nn.3113 · Cited by 786
MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1
Miller, T. E., Ghoshal, K., Ramaswamy, B., Roy, S., Datta, J., Shapiro, C. L., Jacob, S., & Majumder, S. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804612200 · Cited by 749
Druker, B. J., & Lydon, N. B. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9083 · Cited by 707
Development of a Lung Cancer Therapeutic Based on the Tumor Suppressor MicroRNA-34
Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Patrawala, L., Brown, D., & Bader, A. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0655 · Cited by 677
Elmén, J., Lindow, M., Silahtaroglu, A., Bak, M., Christensen, M., Lind-Thomsen, A., Hedtjärn, M., Hansen, J. B., Hansen, H. F., Straarup, E. M., et al. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkm1113 · Cited by 672
miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling
Dávalos, A., Goedeke, L., Smibert, P., Ramírez, C. M., Warrier, N. P., Andreo, U., Cirera-Salinas, D., Rayner, K., Suresh, U., Pastor-Pareja, J. C., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102281108 · Cited by 670
Trang, P., Wiggins, J. F., Daige, C. L., Cho, C., Omotola, M., Brown, D., Weidhaas, J. B., Bader, A. G., & Slack, F. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.48 · Cited by 667
siRNA vs. shRNA: Similarities and differences
Rao, D. D., Vorhies, J. S., Senzer, N., & Nemunaitis, J. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.004 · Cited by 660
Poly(ethylene glycol)-modified Nanocarriers for Tumor-targeted and Intracellular Delivery
van Vlerken, L. E., Vyas, T. K., & Amiji, M. M. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9284-6 · Cited by 645
Ceppi, M., Pereira, P. M., Dunand-Sauthier, I., Barras, E., Reith, W., Santos, M. A., & Pierre, P. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811073106 · Cited by 631
Silencing of microRNA families by seed-targeting tiny LNAs
Obad, S., dos Santos, C. O., Petri, A., Heidenblad, M., Broom, O., Ruse, C., Fu, C., Lindow, M., Stenvang, J., Straarup, E. M., et al. (2011) · Nature Genetics · doi:10.1038/ng.786 · Cited by 627
Therapeutic Inhibition of miR-208a Improves Cardiac Function and Survival During Heart Failure
Montgomery, R. L., Hullinger, T. G., Semus, H. M., Dickinson, B. A., Seto, A. G., Lynch, J. M., Stack, C., Latimer, P. A., Olson, E. N., & van Rooij, E. (2011) · Circulation · doi:10.1161/circulationaha.111.030932 · Cited by 603
HCC and angiogenesis: possible targets and future directions
Zhu, A. X., Duda, D. G., Sahani, D. V., & Jain, R. K. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.30 · Cited by 564
Inhibition of microRNA function by antimiR oligonucleotides
Stenvang, J., Petri, A., Lindow, M., Obad, S., & Kauppinen, S. (2012) · Silence · doi:10.1186/1758-907x-3-1 · Cited by 560
Biodegradable nanoparticles for cytosolic delivery of therapeutics
VASIR, J., & LABHASETWAR, V (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.003 · Cited by 526
Munoz, J. L., Bliss, S. A., Greco, S. J., Ramkissoon, S. H., Ligon, K. L., & Rameshwar, P. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.60 · Cited by 520
Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy
Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.136 · Cited by 515
Self-citationCombining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508
Regression of murine lung tumors by the let-7 microRNA
Trang, P., Medina, P. P., Wiggins, J. F., Ruffino, L., Kelnar, K., Omotola, M., Homer, R., Brown, D., Bader, A. G., Weidhaas, J. B., et al. (2010) · Oncogene · doi:10.1038/onc.2009.445 · Cited by 500
Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma
Babar, I. A., Cheng, C. J., Booth, C. J., Liang, X., Weidhaas, J. B., Saltzman, W. M., & Slack, F. J. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201516109 · Cited by 497
MiR-21 Induced Angiogenesis through AKT and ERK Activation and HIF-1α Expression
Liu, L.-Z., Li, C., Chen, Q., Jing, Y., Carpenter, R., Jiang, Y., Kung, H.-F., Lai, L., & Jiang, B.-H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019139 · Cited by 493
Developing MicroRNA Therapeutics
van Rooij, E., Purcell, A. L., & Levin, A. A. (2012) · Circulation Research · doi:10.1161/circresaha.111.247916 · Cited by 449
Chemical modification and design of anti-miRNA oligonucleotides
Lennox, K. A., & Behlke, M. A. (2011) · Gene Therapy · doi:10.1038/gt.2011.100 · Cited by 433
Improved targeting of miRNA with antisense oligonucleotides
Davis, S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkl183 · Cited by 422
Ghosh, G., Subramanian, I. V., Adhikari, N., Zhang, X., Joshi, H. P., Basi, D., Chandrashekhar, Y. S., Hall, J. L., Roy, S., Zeng, Y., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42980 · Cited by 420
MicroRNAs As Novel Regulators of Angiogenesis
Suárez, Y., & Sessa, W. C. (2009) · Circulation Research · doi:10.1161/circresaha.108.191270 · Cited by 416
Overcoming Nonviral Gene Delivery Barriers: Perspective and Future
Jones, C. H., Chen, C.-K., Ravikrishnan, A., Rane, S., & Pfeifer, B. A. (2013) · Molecular Pharmaceutics · doi:10.1021/mp400467x · Cited by 410
Topical delivery of siRNA-based spherical nucleic acid nanoparticle conjugates for gene regulation
Zheng, D., Giljohann, D. A., Chen, D. L., Massich, M. D., Wang, X.-Q., Iordanov, H., Mirkin, C. A., & Paller, A. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118425109 · Cited by 409
MicroRNA Replacement Therapy for miR-145 and miR-33a Is Efficacious in a Model of Colon Carcinoma
Ibrahim, A. F., Weirauch, U., Thomas, M., Grünweller, A., Hartmann, R. K., & Aigner, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4645 · Cited by 400
Cancer Development, Progression, and Therapy: An Epigenetic Overview
Sarkar, S., Horn, G., Moulton, K., Oza, A., Byler, S., Kokolus, S., & Longacre, M. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141021087 · Cited by 386
Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?
Weiler, J., Hunziker, J., & Hall, J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302654 · Cited by 371
MicroRNAs Reprogram Normal Fibroblasts into Cancer-Associated Fibroblasts in Ovarian Cancer
Mitra, A. K., Zillhardt, M., Hua, Y., Tiwari, P., Murmann, A. E., Peter, M. E., & Lengyel, E. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0206 · Cited by 371
microRNA-205 Regulates HER3 in Human Breast Cancer
Iorio, M. V., Casalini, P., Piovan, C., Di Leva, G., Merlo, A., Triulzi, T., Ménard, S., Croce, C. M., & Tagliabue, E. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2920 · Cited by 365
Liu, X., Chen, Y., Li, H., Huang, N., Jin, Q., Ren, K., & Ji, J. (2013) · ACS Nano · doi:10.1021/nn402201w · Cited by 356
Self-citationRao, X., Di Leva, G., Li, M., Fang, F., Devlin, C., Hartman-Frey, C., Burow, M. E., Ivan, M., Croce, C. M., & Nephew, K. P. (2011) · Oncogene · doi:10.1038/onc.2010.487 · Cited by 342
He, X.-X., Chang, Y., Meng, F.-Y., Wang, M.-Y., Xie, Q.-H., Tang, F., Li, P.-Y., Song, Y.-H., & Lin, J.-S. (2012) · Oncogene · doi:10.1038/onc.2011.500 · Cited by 339
Developing therapeutic microRNAs for cancer
Bader, A. G., Brown, D., Stoudemire, J., & Lammers, P. (2011) · Gene Therapy · doi:10.1038/gt.2011.79 · Cited by 333
Forbes, G. M., Sturm, M. J., Leong, R. W., Sparrow, M. P., Segarajasingam, D., Cummins, A. G., Phillips, M., & Herrmann, R. P. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.06.021 · Cited by 333
Exosomes: Fit to deliver small RNA
Zomer, A., Vendrig, T., Hopmans, E. S., van Eijndhoven, M., Middeldorp, J. M., & Pegtel, D. M. (2010) · Communicative & Integrative Biology · doi:10.4161/cib.3.5.12339 · Cited by 331
MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer
Garofalo, M., Quintavalle, C., Di Leva, G., Zanca, C., Romano, G., Taccioli, C., Liu, C. G., Croce, C. M., & Condorelli, G. (2008) · Oncogene · doi:10.1038/onc.2008.6 · Cited by 289
Delivering the promise of miRNA cancer therapeutics
Pereira, D. M., Rodrigues, P. M., Borralho, P. M., & Rodrigues, C. M. P. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2012.10.002 · Cited by 288
Detecting microRNA binding and siRNA off-target effects from expression data
van Dongen, S., Abreu-Goodger, C., & Enright, A. J. (2008) · Nature Methods · doi:10.1038/nmeth.1267 · Cited by 273
Nielsen, B. S., Jørgensen, S., Fog, J. U., Søkilde, R., Christensen, I. J., Hansen, U., Brünner, N., Baker, A., Møller, S., & Nielsen, H. J. (2011) · Clinical & Experimental Metastasis · doi:10.1007/s10585-010-9355-7 · Cited by 272
Liu, Y., Lai, L., Chen, Q., Song, Y., Xu, S., Ma, F., Wang, X., Wang, J., Yu, H., Cao, X., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1103505 · Cited by 272
Møller, H. G., Rasmussen, A. P., Andersen, H. H., Johnsen, K. B., Henriksen, M., & Duroux, M. (2013) · Molecular Neurobiology · doi:10.1007/s12035-012-8349-7 · Cited by 266
Role of anti-oncomirs miR-143 and -145 in human colorectal tumors
Akao, Y., Nakagawa, Y., Hirata, I., Iio, A., Itoh, T., Kojima, K., Nakashima, R., Kitade, Y., & Naoe, T. (2010) · Cancer Gene Therapy · doi:10.1038/cgt.2009.88 · Cited by 262
MicroRNA regulation of core apoptosis pathways in cancer
Lima, R. T., Busacca, S., Almeida, G. M., Gaudino, G., Fennell, D. A., & Vasconcelos, M. H. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.11.005 · Cited by 260
Han, M., Liu, M., Wang, Y., Chen, X., Xu, J., Sun, Y., Zhao, L., Qu, H., Fan, Y., & Wu, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039520 · Cited by 247
Tivnan, A., Orr, W. S., Gubala, V., Nooney, R., Williams, D. E., McDonagh, C., Prenter, S., Harvey, H., Domingo-Fernández, R., Bray, I. M., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0038129 · Cited by 233
Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer
Wu, Y., Crawford, M., Mao, Y., Lee, R. J., Davis, I. C., Elton, T. S., Lee, L. J., & Nana-Sinkam, S. P. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.14 · Cited by 223
Roles of microRNA on cancer cell metabolism
Chen, B., Li, H., Zeng, X., Yang, P., Liu, X., Zhao, X., & Liang, S. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-228 · Cited by 203
Proviral activation of the putative oncogene Pim-1 in MuLV induced T-cell lymphomas.
Selten, G., Cuypers, H. T., & Berns, A. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb03852.x · Cited by 198
microRNA Replacement Therapy for Cancer
Henry, J. C., Azevedo-Pouly, A., & Schmittgen, T. D. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0548-9 · Cited by 197
Gardner, M. B., Henderson, B. E., Officer, J. E., Rongey, R. W., Parker, J. C., Oliver, C., Estes, J. D., & Huebner, R. J. (1973) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/51.4.1243 · Cited by 197
Shenoy, D., Little, S., Langer, R., & Amiji, M. (2005) · Molecular Pharmaceutics · doi:10.1021/mp0500420 · Cited by 193
Lu, F., Weidmer, A., Liu, C.-G., Volinia, S., Croce, C. M., & Lieberman, P. M. (2008) · Journal of Virology · doi:10.1128/jvi.00752-08 · Cited by 190
MicroRNA-503 targets FGF2 and VEGFA and inhibits tumor angiogenesis and growth
Zhou, B., Ma, R., Si, W., Li, S., Xu, Y., Tu, X., & Wang, Q. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.01.028 · Cited by 188
Horie, T., Ono, K., Nishi, H., Iwanaga, Y., Nagao, K., Kinoshita, M., Kuwabara, Y., Takanabe, R., Hasegawa, K., Kita, T., et al. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.136 · Cited by 186
Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor
Hsu, S.-H., Yu, B., Wang, X., Lu, Y., Schmidt, C. R., Lee, R. J., Lee, L. J., Jacob, S. T., & Ghoshal, K. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2013.05.007 · Cited by 173
A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells
Ghosh, R., Singh, L. C., Shohet, J. M., & Gunaratne, P. H. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.023 · Cited by 172
MicroRNA Delivery by Cationic Lipoplexes for Lung Cancer Therapy
Wu, Y., Crawford, M., Yu, B., Mao, Y., Nana-Sinkam, S. P., & Lee, L. J. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2002076 · Cited by 172
HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells
Matuskova, M., Hlubinova, K., Pastorakova, A., Hunakova, L., Altanerova, V., Altaner, C., & Kucerova, L. (2010) · Cancer Letters · doi:10.1016/j.canlet.2009.08.028 · Cited by 171
Functional Importance of Dicer Protein in the Adaptive Cellular Response to Hypoxia
Ho, J. J. D., Metcalf, J. L., Yan, M. S., Turgeon, P. J., Wang, J. J., Chalsev, M., Petruzziello-Pellegrini, T. N., Tsui, A. K. Y., He, J. Z., Dhamko, H., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.373365 · Cited by 166
Xie, J., Xie, Q., Zhang, H., Ameres, S. L., Hung, J.-H., Su, Q., He, R., Mu, X., Seher Ahmed, S., Park, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.279 · Cited by 166
Targeted Delivery Systems for Oligonucleotide Therapeutics
Yu, B., Zhao, X., Lee, L. J., & Lee, R. J. (2009) · The AAPS Journal · doi:10.1208/s12248-009-9096-1 · Cited by 158
A new role for microRNAs, as ligands of Toll-like receptors
Fabbri, M., Paone, A., Calore, F., Galli, R., & Croce, C. M. (2013) · RNA Biology · doi:10.4161/rna.23144 · Cited by 156
Sureban, S. M., May, R. J., Mondalek, F. G., Qu, D., Ponnurangam, S., Pantazis, P., Anant, S., Ramanujam, R. P., & Houchen, C. W. (2011) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-9-40 · Cited by 154
Anson, D. S. (2004) · Genetic Vaccines and Therapy · doi:10.1186/1479-0556-2-9 · Cited by 154
microRNA, Cell Cycle, and Human Breast Cancer
Yu, Z., Baserga, R., Chen, L., Wang, C., Lisanti, M. P., & Pestell, R. G. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090664 · Cited by 148
Neeße, A., Frese, K. K., Chan, D. S., Bapiro, T. E., Howat, W., Richards, F. M., Ellenrieder, V., Jodrell, D. I., & Tuveson, D. A. (2013) · Gut · doi:10.1136/gutjnl-2013-305559 · Cited by 147
Microenvironmental regulation of cancer metastasis by miRNAs
Zhang, Y., Yang, P., & Wang, X. (2013) · Trends in Cell Biology · doi:10.1016/j.tcb.2013.09.007 · Cited by 147
Chiou, G., Cherng, J., Hsu, H., Wang, M., Tsai, C., Lu, K., Chien, Y., Hung, S., Chen, Y., Wong, C.-I., et al. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.014 · Cited by 146
Self-citationMaintaining the silence: reflections on long-term RNAi
Raemdonck, K., Vandenbroucke, R. E., Demeester, J., Sanders, N. N., & Smedt, S. C. D. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.06.008 · Cited by 132
Virus-modified exosomes for targeted RNA delivery; A new approach in nanomedicine
Koppers‐Lalic, D., Hogenboom, M. M., Middeldorp, J. M., & Pegtel, D. M. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.006 · Cited by 132
MicroRNAs Regulate Tumor Angiogenesis Modulated by Endothelial Progenitor Cells
Plummer, P. N., Freeman, R., Taft, R. J., Vider, J., Sax, M., Umer, B. A., Gao, D., Johns, C., Mattick, J. S., Wilton, S. D., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0271 · Cited by 129
Self-citationMicroRNAs as novel players in skin development, homeostasis and disease: The role of miRNAs in skin
Schneider, M. R. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10568.x · Cited by 118
Delivery Systems and Local Administration Routes for Therapeutic siRNA
Vicentini, F. T. M. C., Borgheti-Cardoso, L. N., Depieri, L. V., Mano, D. D. M., Abelha, T. F., Petrilli, R., & Bentley, M. V. L. B. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-0971-1 · Cited by 115
Stromal expression of SPARC in pancreatic adenocarcinoma
Neuzillet, C., Tijeras‐Raballand, A., Cros, J. F., Faivre, S. J., Hammel, P. R., & Raymond, É. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9439-3 · Cited by 114
Zhang, J., Miao, L., Guo, S., Zhang, Y., Zhang, L., Satterlee, A., Kim, W. Y., & Huang, L. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.016 · Cited by 110
Self-citationSystemic Delivery of microRNA‐34a for Cancer Stem Cell Therapy
Shi, S., Han, L., Gong, T., Zhang, Z., & Sun, X. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201208077 · Cited by 100
Mersey, B. D., Jin, P., & Danner, D. J. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi368 · Cited by 96
Koh, H.-J., Toyoda, T., Fujii, N., Jung, M. M., Rathod, A., Middelbeek, R. J.-W., Lessard, S. J., Treebak, J. T., Tsuchihara, K., Esumi, H., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008131107 · Cited by 94
Pillay, V., Gan, H. K., & Scott, A. M. (2011) · New Biotechnology · doi:10.1016/j.nbt.2011.03.021 · Cited by 91
Kasar, S. N., Salerno, E., Yuan, Y., Underbayev, C., Vollenweider, D., Laurindo, M. F. L., Fernandes, H., Bonci, D., Addario, A., Mazzella, F. M., et al. (2011) · Genes and Immunity · doi:10.1038/gene.2011.58 · Cited by 87
microRNAs are ligands of Toll-like receptors
Chen, X., Liang, H., Zhang, J., Zen, K., & Zhang, C. (2013) · RNA · doi:10.1261/rna.036319.112 · Cited by 87
microRNA-34 family and treatment of cancers with mutant or wild-type p53 (Review)
Yang (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.970 · Cited by 79
Smarter drugs emerging in pancreatic cancer therapy
Kleger, A., Perkhofer, L., & Seufferlein, T. T. W. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu013 · Cited by 78
Concepts in in vivo siRNA delivery for cancer therapy
Gondi, C. S., & Rao, J. S. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21790 · Cited by 75
Nucleobase and Ribose Modifications Control Immunostimulation by a MicroRNA-122-mimetic RNA
Peacock, H., Fucini, R. V., Jayalath, P., Ibarra‐Soza, J. M., Haringsma, H. J., Flanagan, W. M., Willingham, A. T., & Beal, P. A. (2011) · Journal of the American Chemical Society · doi:10.1021/ja202492e · Cited by 75
Synthetic double-stranded RNA oligonucleotides are immunostimulatory for chicken spleen cells
Villanueva, A. I., Kulkarni, R. R., & Sharif, S. (2010) · Developmental & Comparative Immunology · doi:10.1016/j.dci.2010.08.001 · Cited by 72
AEBP1 upregulation confers acquired resistance to BRAF (V600E) inhibition in melanoma
Hu, W., Jin, L., Jiang, C. C., Long, G. V., Scolyer, R. A., Wu, Q., Zhang, X. D., Mei, Y., & Wu, M. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.441 · Cited by 72
Hansen, T. F., Christensen, R. D., Andersen, R. F., Sørensen, F. B., Johnsson, A., & Jakobsen, A. K. M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.448 · Cited by 72
Mesenchymal Stem Cells in drug/gene Delivery: Implications for Cell Therapy
Greco, S. J., & Rameshwar, P. (2012) · Therapeutic Delivery · doi:10.4155/tde.12.69 · Cited by 69
Targeting Cancer Gene Therapy with Magnetic Nanoparticles
Li, C. H., Li, L., & Keates, A. C. (2012) · Oncotarget · doi:10.18632/oncotarget.490 · Cited by 58
Pancreatic stellate cells and fibrosis
Phillips, P. A. (2012) · Cited by 55
Specific protein and miRNA patterns characterise tumour-associated fibroblasts in bladder cancer
Enkelmann, A., Heinzelmann, J., von Eggeling, F., Walter, M., Berndt, A., Wunderlich, H., & Junker, K. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0932-6 · Cited by 49
Competition between Small RNAs: A Quantitative View
Loinger, A., Shemla, Y., Simon, I., Margalit, H., & Biham, O. (2012) · Biophysical Journal · doi:10.1016/j.bpj.2012.01.058 · Cited by 48
Inoue, T., Sugimoto, M., Sakurai, T., Saito, R., Futaki, N., Hashimoto, Y., Honma, Y., Arai, I., & Nakaike, S. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1091 · Cited by 45
Innovative Therapeutic Strategies in the Treatment of Brain Metastases
Caffo, M., Barresi, V., Caruso, G., Cutugno, M., Fata, G. L., Venza, M., Alafaci, C., & Tomasello, F. F. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms14012135 · Cited by 43
Evidence for in vivo macrophage mediated tumor uptake of paramagnetic/fluorescent liposomes
Castelli, D. D., Terreno, E., Cabella, C., Chaabane, L., Lanzardo, S., Tei, L., Visigalli, M., & Aime, S. (2009) · NMR in Biomedicine · doi:10.1002/nbm.1416 · Cited by 43
Chou, J., & Werb, Z. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0465 · Cited by 38
Short Double-Stranded RNA with Immunostimulatory Activity: Sequence Dependence
Kabilova, T., Meschaninova, M., Venyaminova, A., Nikolin, V., Zenkova, M., Vlassov, V., & Chernolovskaya, E. (2012) · Nucleic Acid Therapeutics · doi:10.1089/nat.2011.0328 · Cited by 34
MicroRNA regulation in cancer-associated fibroblasts
Aprelikova, O. N., & Green, J. E. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1139-7 · Cited by 33
Synthetic MicroRNA Cassette Dosing: Pharmacokinetics, Tissue Distribution and Bioactivity
Wang, H., Chiu, M., Xie, Z., Chiu, M. W., Liu, Z., Chen, P., Liu, S., Byrd, J. C., Muthusamy, N., Garzon, R., et al. (2012) · Molecular Pharmaceutics · doi:10.1021/mp2006483 · Cited by 31
Promise and challenge of RNA interference-based therapy for cancer.
Petrocca, F., & Lieberman, J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6287 · Cited by 30
Benwell, R. K., Hruska, J. E., Fritsche, K. L., & Lee, D. R. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.05.008 · Cited by 19
Formstecher, É., Reverdy, C., Cholay, M., Planquette, C., Trouplin, V., Lehrmann, H., Aresta, S., Calabrese, A., Arar, K., Daviet, L., et al. (2006) · Oligonucleotides · doi:10.1089/oli.2006.16.387 · Cited by 16
Emerging therapies in pancreas cancer.
Kotowski, A. S., & Ma, W. W. (2011) · PubMed · doi:10.3978/j.issn.2078-6891.2011.002 · Cited by 12
Biodegradable polymer nanocarriers for therapeutic antisense microRNA delivery in living animals
Paulmurugan, R., Sekar, N. M., & Sekar, T. V. (2012) · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · doi:10.1117/12.914830 · Cited by 11
Cited by
Non-coding RNA networks in cancer
Anastasiadou, E., Jacob, L. S., & Slack, F. J. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.99 · Cited by 1,884
Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance
Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., Wang, Y., Wu, S., Deng, Y., Zhang, J., & Shao, A. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00193 · Cited by 1,451
Hammond, S. M. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.05.001 · Cited by 1,284
Recent progress in drug delivery
Li, C., Wang, J., Wang, Y., Gao, H., Wei, G., Huang, Y., Yu, H., Gan, Y., Wang, Y., Mei, L., et al. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.08.003 · Cited by 818
The Potential for microRNA Therapeutics and Clinical Research
Hanna, J., Hossain, G. S., & Kocerha, J. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00478 · Cited by 726
Metadata
- Authors
- Chen, Y., Gao, D.-Y., & Huang, L.
- Venue
- Advanced Drug Delivery Reviews
- Publisher
- Elsevier BV
- Published
- 2015-01
- Volume
- 81
- Pages
- 128-141
- ISSN
- 0169-409X (ISSN-L)
- OpenAlex
- W2028777474
- Cited by
- 672
- References
- 152
- FWCI
- 2.66
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.